<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006628.pub3" GROUP_ID="SCHIZ" ID="850306090713195135" MERGED_FROM="" MODIFIED="2011-12-07 15:54:46 +0100" MODIFIED_BY="Claire Irving" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2011-12-07 15:54:46 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Zotepine versus other atypical antipsychotics for schizophrenia</TITLE>
<CONTACT MODIFIED="2011-12-07 15:54:46 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="52985282075952777182091104104205" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Selvizhi</FIRST_NAME><LAST_NAME>Subramanian</LAST_NAME><POSITION>Specialist registrar</POSITION><EMAIL_1>selvizhi_s@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Psychiatry</DEPARTMENT><ORGANISATION>Morecambe Community Mental Health Team</ORGANISATION><ADDRESS_1>Victoria House</ADDRESS_1><ADDRESS_2>Thornton RD</ADDRESS_2><CITY>Morecambe</CITY><ZIP>LA4 5NN</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_2>+44 782 433 6497</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-12-07 15:54:46 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="52985282075952777182091104104205" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Selvizhi</FIRST_NAME><LAST_NAME>Subramanian</LAST_NAME><POSITION>Specialist registrar</POSITION><EMAIL_1>selvizhi_s@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Psychiatry</DEPARTMENT><ORGANISATION>Morecambe Community Mental Health Team</ORGANISATION><ADDRESS_1>Victoria House</ADDRESS_1><ADDRESS_2>Thornton RD</ADDRESS_2><CITY>Morecambe</CITY><ZIP>LA4 5NN</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_2>+44 782 433 6497</PHONE_2></ADDRESS></PERSON><PERSON ID="11852B3682E26AA201DC7B3E1C938991" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christine</FIRST_NAME><LAST_NAME>Rummel-Kluge</LAST_NAME><POSITION>Assistenzärztin</POSITION><EMAIL_1>christine.rummel@lrz.tum.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140-6676</PHONE_1><FAX_1>+49-89-4140-6688</FAX_1></ADDRESS></PERSON><PERSON ID="2E84257C82E26AA201BA4B54250245B7" ROLE="AUTHOR"><FIRST_NAME>Heike</FIRST_NAME><LAST_NAME>Hunger</LAST_NAME><EMAIL_1>mailtoHeike@gmx.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+498 941 404247</PHONE_1></ADDRESS></PERSON><PERSON ID="D99E43AC82E26AA201BA4B549DE5F4E8" ROLE="AUTHOR"><FIRST_NAME>Franziska</FIRST_NAME><LAST_NAME>Schmid</LAST_NAME><EMAIL_1>supra.renin@web.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049/89/4140/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="90591E5482E26AA201AA8B42BEBB7D04" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sandra</FIRST_NAME><LAST_NAME>Schwarz</LAST_NAME><EMAIL_1>sandra.schwarz@khsweb.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049/89/4140/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="11850D1F82E26AA201DC7B3E2041CA58" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Werner</FIRST_NAME><LAST_NAME>Kissling</LAST_NAME><POSITION>Leitender Oberarzt</POSITION><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>49-89-4140-4207</PHONE_1><FAX_1>49-89-4140-4894</FAX_1></ADDRESS></PERSON><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Oberarzt</POSITION><EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON><PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katja</FIRST_NAME><LAST_NAME>Komossa</LAST_NAME><POSITION>4th Year Resident (Dr. Med)</POSITION><EMAIL_1>k.komossa@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Moehlstrasse 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049 (0) 89 4141/4247</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-10-06 15:29:57 +0200" MODIFIED_BY="Claire Irving">
<UP_TO_DATE>
<DATE DAY="21" MONTH="5" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="11" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="5" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2011-12-07 15:54:46 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-12-07 15:54:46 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="7" MONTH="12" YEAR="2011"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2011-12-07 15:54:46 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-12-07 15:54:46 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="5" MONTH="10" YEAR="2011"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-10-05 16:52:19 +0200" MODIFIED_BY="Claire Irving"><DATE DAY="10" MONTH="11" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-10 21:34:28 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="6" MONTH="10" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-10-06 15:29:57 +0200" MODIFIED_BY="Claire Irving">
<DATE DAY="1" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Update on comparing the efficacy of zotepine with other second generation antipsychotics. One additional study has been included in this update (<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY></HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-03-27 17:53:58 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-03-27 17:53:54 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-03-27 17:53:38 +0000" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Schizophrenia Group, Nottingham, United Kingdom</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-09-08 14:08:46 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-09-08 09:43:31 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-05-11 16:10:03 +0100" MODIFIED_BY="[Empty name]">Zotepine versus other atypical antipsychotic drugs for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2010-09-08 09:43:31 +0100" MODIFIED_BY="[Empty name]">
<P>This review compares the effects of zotepine to other second generation antipsychotic drugs. Three trials suggest that the efficacy of zotepine may be comparable to risperidone and remoxipride. The evidence base is insufficient to provide firm conclusions as to whether zotepine is as effective or less effective than clozapine. The movement disorders and the cognitive changes appear to be similar to clozapine, risperidone and remoxipride. The need for antiparkinson medication is similar to risperidone and remoxipride, but may be associated with increased need than necessary with clozapine.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-09-08 13:41:52 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-05-17 11:02:35 +0100" MODIFIED_BY="[Empty name]">
<P>In many parts of the world, particularly in industrialised countries, second generation (atypical) antipsychotic drugs have become first line treatment for people suffering from schizophrenia. The question as to whether the effects of various second generation antipsychotic drugs differ is a matter of debate.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-08-03 15:33:41 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the effects of zotepine compared with other second generation antipsychotic drugs for people suffering from schizophrenia and schizophrenia-like psychoses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-05-17 11:03:25 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group Trials Register (November 2009), inspected references of all identified studies for further trials and contacted authors of trials for additional information.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-08-03 15:33:58 +0100" MODIFIED_BY="[Empty name]">
<P>We included only randomised clinical controlled trials that compared zotepine with any forms of amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole or ziprasidone in people suffering from only schizophrenia or schizophrenia-like psychoses.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-09-08 13:41:52 +0100" MODIFIED_BY="[Empty name]">
<P>SS and KK extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. For continuous data, we calculated weighted mean differences (MD) again based on a random-effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-09-08 09:40:43 +0100" MODIFIED_BY="[Empty name]">
<P>We included three studies (total n=289; 2 RCTs zotepine vs clozapine; 1 RCT zotepine vs clozapine vs risperidone (at 4 mg, 8 mg doses) vs remoxipride. All studies were of limited methodological quality. When zotepine was compared with clozapine, it was clozapine that was found to be more effective in terms of global state (n=59, 1 RCT, RR No clinically significant response 8.23 CI 1.14 to 59.17). Mental state scores also favoured clozapine (n=59, 1 RCT, MD average score (BPRS total, high = poor) 6.00 CI 2.17 to 9.83) and there was less use of antiparkinson medication in the clozapine group (n=116, 2 RCTs, RR 20.96 CI 2.89 to 151.90). In the comparison of zotepine and risperidone, mental state scoring found no significant difference between the groups (vs 4 mg: n=40, 1 RCT, MD average endpoint score (BPRS total, high=poor) 1.40 CI -9.82 to 12.62; vs 8 mg: n=40,<B> </B>1 RCT, MD -1.30 CI -12.95 to 10.35) and use of antiparkinson medication was equivocal (vs 4 mg: n=40, 1 RCT, MD 1.80 CI -0.64 to 4.24; vs 8 mg: n=40,<B> </B>1 RCT, MD 2.50 CI -0.05 to 5.05). Finally, when zotepine was compared with remoxipride, again no effect was found for mental state (n=58, 1 RCT, MD average endpoint score (BPRS total, high=poor) 5.70 CI -4.13 to 15.53) and there was no significant difference between the two groups in terms of use of antiparkinson medication (n=49, 1 RCT, RR 0.97 CI 0.41 to 2.29).</P>
<P>Data on important other outcomes such as other adverse events, service use or satisfaction with care, quality of life were not available.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-05-17 11:25:55 +0100" MODIFIED_BY="[Empty name]">
<P>The evidence base around zotepine is insufficient to provide firm conclusions on its absolute or relative effects. This is despite it being in use in Austria, France, Germany, Japan and the UK.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-09-08 14:08:46 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-09-08 09:45:30 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2010-08-03 15:42:08 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is usually a chronic and disabling psychiatric disorder which affects approximately 1% of the population world-wide. The annual incidence of schizophrenia averages about 15 people per 100000 (point prevalence approximately 4.5/1000, life time risk 0.7% (<LINK REF="REF-Tandon-2008" TYPE="REFERENCE">Tandon 2008</LINK>)). The typical manifestations are positive symptoms such as fixed, false beliefs (delusions), perceptions without cause (hallucinations), negative symptoms such as apathy and lack of drive, disorganisation of behaviour and thought, catatonic symptoms such as mannerisms and bizarre posturing (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). The degree of disability is considerable with 80-90% of people unable to work (<LINK REF="REF-Marvaha-2004" TYPE="REFERENCE">Marvaha 2004</LINK>) and up to 10% dying from suicide (<LINK REF="REF-Tsuang-1978" TYPE="REFERENCE">Tsuang 1978</LINK>). In the 15-44 years age range, schizophrenia is among the top ten causes of disease-related disability in the world (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-08-02 15:46:44 +0100" MODIFIED_BY="[Empty name]">
<P>Traditionally, the conventional antipsychotic drugs such as chlorpromazine and haloperidol have been used as first line antipsychotic drugs for people suffering from schizophrenia (<LINK REF="REF-Kane-1993" TYPE="REFERENCE">Kane 1993</LINK>). Clozapine was introduced in USA in 1990. It was discovered that clozapine appeared to be more effective and associated with fewer movement disorders than chlorpromazine (<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>). This boosted the development of so-called atypical or newer or second generation antipsychotic drugs (SGA). These drugs promised an improvement in the management of schizophrenia in a number of areas such as improving compliance, cognitive functioning, negative symptoms, movement disorders, quality of life and treatment resistance. There is no clear cut definition of what an 'atypical' antipsychotic drug is. However, they are thought to differ from typical antipsychotic drugs in that they do not cause movement disorders (catalepsy) in rats at clinically effective doses (<LINK REF="REF-Arnt-1998" TYPE="REFERENCE">Arnt 1998</LINK>). The term 'newer drug' is not ideal, as for example, clozapine was formulated in the early 1960s. According to treatment guidelines (<LINK REF="REF-APA-2004" TYPE="REFERENCE">APA 2004</LINK>, <LINK REF="REF-Gaebel-2006" TYPE="REFERENCE">Gaebel 2006</LINK>) the second generation antipsychotic drugs include amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine. It is, however, unclear whether some old and inexpensive compounds such as sulpiride or perazine have similar properties (<LINK REF="REF-M_x00f6_ller-2000" TYPE="REFERENCE">Möller 2000</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2010-08-02 15:47:51 +0100" MODIFIED_BY="[Empty name]">
<P>Zotepine is a second generation antipsychotic drug with a high affinity for human D1-like (D1, D5) and D2-like (D2, D3, D4) dopamine receptors and serotonin subtypes (5HT2a, 5HT2c, 5HT6, 5HT7; <LINK REF="REF-Leysen-1993" TYPE="REFERENCE">Leysen 1993</LINK>, <LINK REF="REF-Roth-1994" TYPE="REFERENCE">Roth 1994</LINK>, <LINK REF="REF-Needham-1996" TYPE="REFERENCE">Needham 1996</LINK>). It also inhibits norepinephrine re-uptake and it is claimed to be particularly effective for negative symptoms (<LINK REF="REF-DeSilva-2006" TYPE="REFERENCE">DeSilva 2006</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-09-08 09:45:30 +0100" MODIFIED_BY="[Empty name]">
<P>Despite the debate as to whether second generation antipsychotic drugs are better than conventional neuroleptics (<LINK REF="REF-Duggan-2005" TYPE="REFERENCE">Duggan 2005</LINK>, <LINK REF="REF-El_x002d_Sayeh-2006" TYPE="REFERENCE">El-Sayeh 2006</LINK>, <LINK REF="REF-Lieberman-2005" TYPE="REFERENCE">Lieberman 2005</LINK>, <LINK REF="REF-Jones-2006" TYPE="REFERENCE">Jones 2006</LINK>). In some parts of the world, particularly in industrialised countries, the second generation antipsychotic drugs have become the mainstay of treatment. Therefore, it is important to review the effects of these drugs in head-to-head comparisons.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-05-17 12:08:28 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficiency and tolerability of zotepine compared with other second generation antipsychotic drugs for people suffering from schizophrenia and schizophrenia-like psychoses.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-09-08 10:07:57 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-08-02 15:50:27 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-08-02 15:49:34 +0100" MODIFIED_BY="[Empty name]">
<P>We searched for only randomised controlled trials, irrespective of the blinding status, published in all languages. We approached relevant translators, to clarify the type of trial and where necessary to collect the data. We excluded case series, diagnostic studies, non-randomised, quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-05-17 12:08:55 +0100" MODIFIED_BY="[Empty name]">
<P>We included trials that intervened with people suffering from schizophrenia and schizophrenia-like psychosis (e.g. schizophreniform and schizoaffective disorders), irrespective of the diagnostic criteria used. There is no clear evidence that the schizophrenia-like psychoses are caused by fundamentally different disease processes or that they require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-04-26 13:00:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Zotepine: oral form of application, any dose.<BR/>2. Other second generation antipsychotic drugs: amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole, ziprasidone: any form of application, any dose.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-08-02 15:50:27 +0100" MODIFIED_BY="[Empty name]">
<P>We grouped the outcomes into the short term (up to 12 weeks), medium term (13-26 weeks) and long term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-08-02 15:50:27 +0100" MODIFIED_BY="[Empty name]">
<P>No clinically important response: as defined by the individual studies (e.g. global impression less than much improved or less than 50% reduction on a rating scale).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-10-20 16:43:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Leaving the studies early (any reason, adverse events, inefficacy of treatment)</P>
<P>2. Global state<BR/>2.1 No clinically important change in global state (as defined by individual studies)<BR/>2.2 Relapse (as defined by the individual studies)</P>
<P>3. Mental state (with particular reference to the positive and negative symptoms of schizophrenia)<BR/>3.1 No clinically important change in general mental state score<BR/>3.2 Average endpoint general mental score<BR/>3.3 Average change in general mental state score<BR/>3.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia)<BR/>3.5 Average endpoint specific symptom score<BR/>3.6 Average change in specific symptom score</P>
<P>4. General functioning<BR/>4.1 No clinically important change in general functioning<BR/>4.2 Average endpoint general functioning score<BR/>4.3 Average change in general functioning score</P>
<P>5. Quality of life/satisfaction with treatment<BR/>5.1 No clinically important change in general quality of life<BR/>5.2 Average endpoint general quality of life score<BR/>5.3 Average change in general quality of life score</P>
<P>6. Cognitive functioning<BR/>6.1 No clinically important change in overall cognitive functioning<BR/>6.2 Average endpoint of overall cognitive functioning score<BR/>6.3 Average change of overall cognitive functioning score</P>
<P>7. Service use<BR/>7.1 Number admitted to hospital</P>
<P>8. Adverse effects<BR/>8.1 Number with at least one adverse effect<BR/>8.2 Clinically important specific adverse effects (cardiac effects, death, movement disorders, prolactin increase and associated effects, sedation, seizures, weight gain, effects on white blood cell count)<BR/>8.3 Average endpoint in specific adverse effects<BR/>8.4 Average change in specific adverse effects</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-09-08 10:07:57 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2010-09-08 10:07:57 +0100" MODIFIED_BY="[Empty name]">
<P>For this, the 2010 update, we searched the Cochrane Schizophrenia Group Trials Register (November 2009). The register was searched using the phrase:</P>
<P>[(*zotepine* or *lodopin* or *nipolept* or *zopite* or *setous* or *majorpin* in STUDY intervention field)]</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see <A HREF="http://szg.cochrane.org/cochrane-schizophrenia-group-specialised-register">Group Module</A>).</P>
<P>The search undertaken in 2007 is outlined in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-05-11 20:52:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Reference searching<BR/>We inspected reference lists of all identified studies for more trials.</P>
<P>2. Personal contact<BR/>We contacted the first author of each included study for missing information. When there was no response or where information was not available from the first author, we then contacted the other authors enlisted in the study.</P>
<P>3. Drug companies<BR/>We contacted manufacturers of the included second generation antipsychotic drugs for additional data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-08-03 15:45:00 +0100" MODIFIED_BY="[Empty name]">
<P> </P>
<STUDY_SELECTION MODIFIED="2010-04-27 18:53:45 +0100" MODIFIED_BY="[Empty name]">
<P>SS and KK independently inspected all reports. We resolved any disagreement by discussion, and where there was still doubt, we acquired the full article for further inspection. Once the full articles were obtained, we decided independently whether the studies met the review criteria. If disagreement could not be resolved by discussion, we sought further information and added these trials to the list of those awaiting assessment.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-08-03 15:36:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Data extraction<BR/>SS and KK independently extracted data from the selected trials. When disputes arose we attempted to resolve these by discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter the data but added the trial to the list of those awaiting assessment and sought more information.</P>
<P>2. Data management<BR/>2.1 Continuous<BR/>2.1.1 Skewed data<BR/>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion: a) standard deviations and means are reported in the paper or obtainable from the authors; b) when a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); c) if a scale starts from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above will be modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied. When continuous data are presented on a scale which includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. Skewed data from studies of less than 200 participants were entered in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at means if the sample size is large and were entered into syntheses.</P>
<P>2.1.2 Conversion of continuous to binary<BR/>Where possible, efforts were made to convert outcome measures to dichotomous data. This could be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>, <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). If data based on these thresholds were not available, we used the primary cut -off presented by the original authors.</P>
<P>2.2 Rating scales<BR/>2.2.1 Valid scales<BR/>A wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are of questionable validity, or even 'ad hoc'. It is accepted generally that measuring instruments should have the properties of reliability and validity (<LINK REF="REF-Rust-1989" TYPE="REFERENCE">Rust 1989</LINK>). Unpublished scales are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore continuous data from rating scales were included only if the measuring instrument had been described in a peer -reviewed journal. In addition, the following minimum standards for instruments were set: the instrument should either be (a) a self -report or (b) completed by an independent rater or relative (not the therapist) and (c) the instrument should be a global assessment of an area of functioning.</P>
<P>2.2.2 Endpoint versus change data<BR/>We preferred to use scale endpoint data, which typically cannot have negative values and is easier to interpret from a clinical point of view. Change data are often not ordinal and are very problematic to interpret. If endpoint data were unavailable we used change data.</P>
<P>3. Common measure<BR/>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).</P>
<P>4. Direction of graphs<BR/>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for zotepine.</P>
<P>5. Summary of findings table<BR/>We anticipate including the following long-term main outcomes in a Summary of Findings table:</P>
<P>1. Mental state<BR/>1.1 General symptoms - no clinically important improvement<BR/>1.2 Specific symptoms<BR/>1.2.1 Negative symptoms (poor volition, poor self-care, blunted affect) - no clinically important improvement</P>
<P>2. Global state<BR/>2.1 Relapse (as defined in trial)<BR/>2.2 Not improved to a clinically meaningful extent (as defined in trial)<BR/>
</P>
<P>3. Behaviour<BR/>3.1 General behaviour - no clinically important improvement<BR/>
</P>
<P>4. Adverse effects<BR/>4.1 General problems<BR/>4.2 Specific problems - important disabling problem</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-05-17 12:11:05 +0100" MODIFIED_BY="[Empty name]">
<P>SS and KK independently assessed risk of bias using the tool described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. We would have excluded studies where allocation was clearly not concealed.</P>
<P>Trials with high risk of bias (defined as at least three out of six domains categorised as 'No') were removed from the 'included' category. If the raters disagreed, the final rating was made by consensus with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials are provided, authors of the studies were contacted in order to obtain further information. Non-concurrence in quality assessment was reported.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-05-12 12:45:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Binary data<BR/>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>).</P>
<P>2. Continuous data<BR/>2.1 Summary statistic<BR/>For continuous outcomes we estimated a mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, where scales were of such similarity to allow presuming there was a small difference in measurement, we calculated it and, whenever possible, we transformed the effect back to the units of one or more of the specific instruments.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-08-03 15:45:00 +0100" MODIFIED_BY="[Empty name]">
<P>1. Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This can cause type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering is not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intraclass correlation coefficients for their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering had been incorporated into the analysis of primary studies, we present these data as if from a non -cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra -class correlation coefficient (ICC) [Design effect = 1 + (m -1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies has been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
<P>2. Cross-over trials<BR/>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in severe mental illness, we will only use data of the first phase of cross-over studies.</P>
<P>3. Studies with multiple treatment groups<BR/>Where a study involved more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. Where the additional treatment arms were not relevant, these data were not reproduced.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-05-17 12:12:47 +0100" MODIFIED_BY="[Empty name]">
<P>1. Overall loss of credibility<BR/>At some degree of loss of follow-up data must lose credibility (<LINK REF="REF-Xia-2007" TYPE="REFERENCE">Xia 2007</LINK>). For any particular outcome should more than 50% of data be unaccounted for, we did not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we marked such data with (*) to indicate that such a result may well be prone to bias.</P>
<P>2. Binary<BR/>In the case where attrition for a binary outcome is between 0 and 50% and where these data were not clearly described, data were presented on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis). Those lost to follow up were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death. A sensitivity analysis was undertaken testing how prone the primary outcomes were to change when 'completed' data only were compared to the intention-to-treat analysis using the above assumption.</P>
<P>3. Continuous<BR/>3.1 Attrition<BR/>In the case where attrition for a continuous outcome is between 0 and 50% and completer-only data were reported, we have reproduced these.</P>
<P>3.2 Standard deviations<BR/>3.2.1 General<BR/>Where there are missing measures of variance for continuous data but an exact standard error and confidence interval are available for group means, either &#8216;p&#8217; value or 't' value are available for differences in mean, we will calculate standard deviation value according to methods described in Section 7.7.3 of the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>; <LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). If standard deviations were not reported and could not be calculated from available data, we asked authors to supply the data. In the absence of data from authors, we used the mean standard deviation from other studies.</P>
<P>3.2.2 Standard deviation mean number of days per month in hospital<BR/>For the primary outcome, mean number of days per month in hospital, if standard deviations were not reported and could not be calculated from available data, we asked authors for additional information. In the absence of data from authors, we calculated missing standard deviations using a regression analysis of standard deviation against mean, based on data from studies which did report these data.</P>
<P>3.3 Last observation carried forward<BR/>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results. Therefore, where LOCF data has been used in the trial, if less than 50% of the data had been assumed, we reproduced these data and indicated that they are the product of LOCF assumptions.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-07-20 15:31:05 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical heterogeneity<BR/>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying situations or people which we had not predicted would arise. Should such situations or participant groups have arisen they were fully discussed.</P>
<P>2. Methodological heterogeneity<BR/>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. Should such methodological outliers have arisen they were fully discussed.</P>
<P>3. Statistical<BR/>3.1 Visual inspection<BR/>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
<P>3.2 Employing the I<SUP>2</SUP>statistic<BR/>Heterogeneity between studies was investigated by considering the I<SUP>2</SUP> method alongside the Chi<SUP>2</SUP> 'p' value. The I<SUP>2</SUP> provides an estimate of the percentage of <BR/>inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of I<SUP>2</SUP> depends on i. magnitude and direction of effects and ii. <BR/>strength of evidence for heterogeneity (e.g. 'p' value from Chi<SUP>2</SUP> test, or a confidence interval for I<SUP>2</SUP>).</P>
<P>I<SUP>2</SUP> estimate greater than or equal to 50% accompanied by a statistically significant Chi<SUP>2</SUP> statistic, was interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 - <LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and reasons for heterogeneity were explored. If the inconsistency was high and the clear reasons were found, data were presented separately.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-05-17 11:26:57 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in Section 10 of the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small -study effects. We did not use funnel plots for outcomes where there were ten or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-08-02 15:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>Where possible we employed a random-effect model for analyses. We understand that there is no closed argument for preference for use of fixed or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us, however, random-effects does put added weight onto the smaller of the studies, those trials that are most vulnerable to bias.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-05-17 12:14:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Subgroup analyses<BR/>We anticipated no sub-group analyses.</P>
<P>2. Investigation of heterogeneity<BR/>2.1 Unanticipated heterogeneity<BR/>Should unanticipated clinical or methodological heterogeneity be obvious we will simply state hypotheses regarding these for future reviews or versions of this review. We do not anticipate undertaking analyses relating to these.</P>
<P>2.2 Anticipated heterogeneity<BR/>We did not anticipate any heterogeneity.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-05-12 12:37:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Implication of randomisation<BR/>We aimed to include trials in a sensitivity analysis if they are described in some way as to imply randomisation. For the primary outcomes we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then all data were employed from these studies.</P>
<P>2. Assumptions for lost binary data<BR/>Where assumptions had to be made regarding people lost to follow up (see Dealing with missing data) we compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there was a substantial difference, we reported results and discuss them but continued to employ our assumption.</P>
<P>3. Skewed data<BR/>In the sensitivity analyses we excluded outcomes with skewed data. </P>
<P>4. Inappropriate comparator doses<BR/>A recent report showed that some of the comparisons of second generation antipsychotic drugs may have been biased by using inappropriate comparator doses (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). We, therefore, analysed whether the exclusion of studies with inappropriate comparator doses changed the results of the primary outcome and the general mental state.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-09-08 14:08:46 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-09-08 14:08:46 +0100" MODIFIED_BY="[Empty name]">
<P>For substantive description of studies please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2010-09-08 09:48:21 +0100" MODIFIED_BY="[Empty name]">
<P>The search strategy yielded 54 references (from 34 studies). Reports were closely inspected. After excluding ten, we were only able to include three studies. Among the included studies, two compared zotepine with clozapine and one trial compared zotepine with clozapine, risperidone (at 4 mg, 8 mg doses) and remoxipride. Remoxipride is an atypical antipsychotic which was used in Europe in the past, but has been withdrawn due to concerns about toxicity. We included the comparison with remoxipride for completeness and it may assist researchers.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-09-08 14:08:46 +0100" MODIFIED_BY="[Empty name]">
<P>Three randomised trials with 289 participants met the inclusion criteria. <LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> was a parallel, double blind trial (sponsor unclear). <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> was a parallel, single blind trial (blinded raters) conducted in China (sponsor unclear). <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> was a parallel, double-blind trial (sponsored by zotepine's manufacturer).</P>
<P>1. Length of studies<BR/>
<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> was conducted over a period of four weeks, <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> over six and <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> over twelve.<BR/>
<BR/>2. Setting<BR/>
<LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> was a hospital-based study, while <LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK>and <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> did not report the setting.</P>
<P>3. Participants<BR/>
<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> included people suffering from acute paranoid hallucinatory schizophrenia (295.3) diagnosed using International Classification of Diseases-9. <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> included people suffering from schizophrenia, but did not specify the diagnostic criteria used. <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> included people suffering from schizophrenia, diagnosed using Diagnostic and Statistical Manual Version III (DSM-III).</P>
<P>4. Study size<BR/>
<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> included 180 people. Both <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> and <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> studies were smaller with only 50 participants each.</P>
<P>5. Interventions<BR/>British National Formulary (<A HREF="http://bnf.org/bnf/index.htm">BNF</A>) recommends zotepine for people suffering from schizophrenia. The starting dose is 25 mg, three times daily, increased according to response at intervals of 4 days, to a maximum of 300 mg per day in three divided doses. Different doses are recommended for the elderly and it is not recommended for children and adolescents.</P>
<P>5.1 Zotepine<BR/>
<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> used zotepine at a fixed dose of 225 mg/day. Zotepine was given in flexible doses in the other two studies. The dose range in <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> was 150 to 450 mg/day. <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> did not report the dose range of zotepine, but the average dose was 387 mg/day.</P>
<P>5.2 Comparison drugs<BR/>
<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> used risperidone 4mg and 8 mg, clozapine 400mg, remoxipride 400mg, haloperidol 15 mg as comparators. We did not compare the effectiveness of zotepine with haloperdiol as this is a typical antipsychotic and hence does not address the objective of our review. In <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> the range was 150-450 mg/day. <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> and <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> used only clozapine as a comparator. <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> did not report the range of the dose of clozapine, but the average daily dose was 377 mg/day.</P>
<P>6. Outcomes<BR/>6.1 General<BR/>
<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> reported details of total average end point Brief Psychiatry Rating Scale (BPRS) score, average end point extrapyramidal symptom (EPS) score, use of antiparkinson medication, changes in syndrome short test. <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> used 'at least much improved' as a criterion for response to treatment. <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> reported values on &#8216;no clinically important response&#8217;, average BPRS score, average change of prolactin from baseline, use of antiparkinson medication. <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> reported numbers leaving early for any reason, but the specific reasons for leaving the study early (adverse events, lack of efficacy) were not presented. All other outcomes were reported only for a small subgroup of matched participants and therefore could not be used in this review.</P>
<P>6.2 Outcome scales<BR/>Details of scales that provided usable data are shown below. Reasons for exclusion of data from other instruments are given under 'Outcomes' in the Included studies section.</P>
<P>6.2.1 Mental state<BR/>6.2.1.1 Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven -point scale varying from 'not present' to 'extremely severe', scoring from 0-6 or 1-7. Scores can range from 0-126, with high scores indicating more severe symptoms.</P>
<P>6.2.2 Adverse effects<BR/>6.2.2.1 Simpson Angus scale - SAS (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This is used to assess parkinsonian and related extrapyramidal side effects in clinical practice. It is a clinician-rated 10-item rating scale.</P>
<P>6.2.3 Cognitive functioning<BR/>6.2.3.1 Syndrome kurz test - SKT <LINK REF="REF-Erzigkeit-1989" TYPE="REFERENCE">Erzigkeit 1989</LINK>
<BR/>SKT is a brief neuropsychological test battery to test memory and attention deficit. High scores indicate more severe symptoms.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-09-08 09:57:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Excluded studies<BR/>The search strategy identified 54 references. Thirteen studies relevant to this review were closely inspected, of which ten had to be excluded. Among the excluded ten studies, three were found to be case series and two were diagnostic studies. One was open label non-randomised study and another was a naturalistic study. One was a placebo controlled trial. <LINK REF="STD-Perro-1999" TYPE="STUDY">Perro 1999</LINK> was a randomised trial with 75 participants, which compared zotepine with risperidone, olanzapine and sertindole. The intended outcomes were a series of scales (PANSS, CGI, GAF, UKU, BDI, SCL-R 90, QLS) but there were no data available in the report. We contacted one of the authors for more details, who confirmed that the full report, along with rest of the data, was not published anywhere. It had to be excluded. <LINK REF="STD-Briken-2002" TYPE="STUDY">Briken 2002</LINK> was a randomised controlled trial, which evaluated the effect of zotepine compared with risperidone and olanzapine on hostility in people with schizophrenia. The number of participants in each arm were unclear. Outcomes proposed were PANSS, UKU, PANSS-EC - but no data were available, as confirmed by one of its authors. Hence this study also had to be excluded. All trials found in other languages were either case series or diagnostic studies and were excluded.</P>
<P>2. Awaiting assessment<BR/>No studies await assessment.</P>
<P>3. Ongoing studies<BR/>
<LINK REF="STD-Tsai-2007" TYPE="STUDY">Tsai 2007</LINK> is an ongoing multi-centre open label, randomised trial, evaluating the anti-aggression effect and safety of zotepine versus risperidone in aggressive people with schizophrenia in an acute ward. The study includes 160 adults of mixed gender. PANSS-EC is used as the primary outcome and PANSS, CGI scores are secondary outcomes.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-05-17 12:19:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> did not give details of sequence generation or allocation concealment suggesting that it is prone for bias. <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> gave values of a matched subsamples only. <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> was poorly reported and is prone to considerable risk of bias. For details please refer to <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2010-03-30 15:15:48 +0100" MODIFIED_BY="[Empty name]">
<P>All three included studies were randomised, but details of the randomisation process were not provided.</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-05-17 12:18:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> and <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> were double-blind and <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> was single-blind (blinded raters), but further details on the blinding procedure were not provided in any of these studies. None of the studies tested whether blinding was successful. Blinding may be less important for objective outcomes, but the latter two studies reported only subjective outcomes.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-04-26 18:13:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> appears to have had no loss to follow up, but this has not been explicitly described. <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> reported only leaving the study early because of &#8216;any reason&#8217;, but specific reasons for leaving the study early were not indicated. Furthermore, the overall attrition was considerable (34%) limiting validity of the findings. <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> did not provide any data on people leaving the study early.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-05-17 12:19:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> has reported the data comprehensively. <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> is only available as an abstract in which only a few outcomes (global state, use of antiparkinson medication, prolactin increase and mental state) have been reported. The only usable outcome of <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> was leaving the study early. All other outcomes have only been reported for a matched (i.e. no longer randomised) sub-sample.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-05-17 12:19:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> has described EPS values, but it should be noted that biperiden co-medication was permitted. The frequency of the medication administered appears to be dependent on the preparation, but the criteria for using the biperiden has not been made clear.</P>
<P>
<LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> was sponsored by the manufacturers of zotepine. It has been shown that pharmaceutical companies tend to emphasise the advantages of their drugs and to highlight the problems of comparator compounds (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>).</P>
<P>
<LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> used an "enriched design". All participants had been on stable doses of clozapine before the study and were then randomised to either continuation of clozapine or switch to zotepine. This design could confer advantage for clozapine.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-09-08 09:58:50 +0100" MODIFIED_BY="[Empty name]">
<P>1. Comparison 1. ZOTEPINE versus CLOZAPINE - all short term outcomes (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>)</P>
<P>This comparison includes data from all three trials with 166 people in groups relevant to this question.<BR/>
<BR/>1.1 Global state<B>
<BR/>
</B>1.1.1 No clinically significant response - as defined by the original studies (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)<BR/>There was a significant difference favouring clozapine (n=59, 1 RCT, RR 8.23 CI 1.14 to 59.17).</P>
<P>1.2 Leaving the study early (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>)<BR/>There was no clear difference between groups, but about 34% of people in this short study left early (n= 50, 1 RCT, RR 1.43 CI 0.65 to 3.15).<BR/>
<BR/>1.3 Mental state<BR/>1.3.1. Average score (BPRS total, high = poor) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>)<BR/>There was a significant difference favouring clozapine (n=59, 1 RCT, MD 6.00 CI 2.17 to 9.83).</P>
<P>1.3.2. Average endpoint score (BPRS total, high=poor) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>)<BR/>There was no significant difference between the two groups (n=57, 1 RCT, MD 2.20 CI -7.77 to 12.17).</P>
<P>1.4 Adverse effects<BR/>1.4.1 Extrapyramidal effects - Average end point EPS score (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>)<BR/>There was no significant difference in the end point EPS values between the groups (n=57, 1 RCT, MD 2.10 CI -0.25 to 4.45).</P>
<P>1.4.2 Extrapyramidal effects - use of antiparkinson medication (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>)<BR/>There was a significant difference in use of antiparkinson medication favouring clozapine in both <LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> and <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> studies. This significance was greater when the results of these two studies were combined (n=116, 2 RCT, RR 20.96 CI 2.89 to 151.90).</P>
<P>1.4.3 Prolactin &#8211; average change from baseline (ng/ml) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>)<BR/>There was a significant difference favouring clozapine (n=59, 1 RCT, MD 33.40 CI 14.87 to 51.93).</P>
<P>1.5 Cognitive functioning<BR/>1.5.1 Cognitive functioning - not improved (SKT) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>)<BR/>There was no significant difference between the groups (n=57, 1 RCT, RR 0.57 CI 0.21 to 1.52).</P>
<P>1.5 Publication bias<BR/>Due to small number of included studies we did not perform a funnel plot analysis.</P>
<P>1.6 Investigation for heterogeneity and sensitivity analysis<BR/>The reasons for the preplanned sensitivity analyses did not apply and were therefore not performed.</P>
<P>2. Comparison 1. ZOTEPINE versus RISPERIDONE 4 mg, 8 mg - all short term outcomes (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>)</P>
<P>This comparison includes only <LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> with 60 people in relevant groups.</P>
<P>2.1 Mental state<BR/>2.1.1. Average endpoint score (BPRS total, high=poor) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)<BR/>There was no significant difference between the two groups (vs 4 mg: n=40, 1 RCT, MD 1.40 CI -9.82 to 12.62; vs 8 mg: n=40,<B> </B>1 RCT, MD -1.30 CI -12.95 to 10.35).</P>
<P>2.2 Adverse effects<BR/>2.2.1 Extrapyramidal effects - Average end point EPS score (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>)<BR/>There was no significant difference in the end point EPS scores when compared zotepine with risperidone (vs 4 mg: n=40, 1 RCT, MD 1.80 CI -0.64 to 4.24; vs 8 mg: n=40,<B> </B>1 RCT, MD 2.50 CI -0.05 to 5.05).</P>
<P>2.2.2 Extrapyramidal effects - use of antiparkinson medication (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>)<BR/>There was no significant difference in the use of antiparkinson medication, when zotepine was compared with risperidone (vs 4 mg: n=40, 1 RCT, MD 1.80 CI -0.64 to 4.24; vs 8 mg: n=40,<B> </B>1 RCT, MD 2.50 CI -0.05 to 5.05).</P>
<P>2.3 Cognitive functioning<BR/>2.3.1 Cognitive functioning - not improved (SKT) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>)<BR/>There was no significant difference between the zotepine and the risperidone groups (vs 4 mg: n=40, 1 RCT, MD 0.80 CI 0.25 to 2.55; vs 8 mg: n=40,<B> </B>1 RCT, MD 1.00 CI 0.29 to 3.45).</P>
<P>3. Comparison 1. ZOTEPINE versus REMOXIPRIDE - all short term outcomes (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>)</P>
<P>This comparison includes only <LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> with 58 people in relevant groups.</P>
<P>3.1 Mental state<BR/>3.1.1. Average endpoint score (BPRS total, high=poor) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)<BR/>There was no significant difference between the two groups (n=58, 1 RCT, MD 5.70 CI -4.13 to 15.53).</P>
<P>3.2 Adverse effects<BR/>3.2.1 Extrapyramidal effects - Average end point EPS score (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>)<BR/>There was no significant difference in the end point EPS values between the groups (n=58, 1 RCT, MD 0.00 CI -2.62 to 2.62).</P>
<P>3.2.2 Extrapyramidal effects - use of antiparkinson medication (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>)<BR/>There was no significant difference between the two groups (n=49, 1 RCT, RR 0.97 CI 0.41 to 2.29).</P>
<P>3.3 Cognitive functioning<BR/>3.3.1 Cognitive functioning - not improved (SKT) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>)<BR/>There was no significant difference between the groups (n=58, 1 RCT, RR 0.69 CI 0.25 to 1.89).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-09-08 10:03:35 +0100" MODIFIED_BY="[Empty name]">
<P> </P>
<SUMMARY_OF_RESULTS MODIFIED="2010-08-03 15:22:13 +0100" MODIFIED_BY="[Empty name]">
<P>We identified three studies which compared zotepine with other atypical antipsychotic medications. The total number of participants was 289. <LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> reported details of total average end point Brief Psychiatry Rating Scale (BPRS) score, average end point extra pyramidal symptom (EPS) score, use of antiparkinson medication, changes in syndrome short test. <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> used 'at least much improved' as a criterion for response to treatment. <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> was presented only as an abstract and reported values on "no clinically important response" (as defined by the original studies), average BPRS score, average change of prolactin from baseline, use of antiparkinson medication. <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> reported numbers leaving early for any reason, but the specific reasons for leaving the study early (adverse events, lack of efficacy) were not presented. All other outcomes were reported only for a small subgroup of matched participants. Therefore, for most outcomes of interest no relevant information was available. Though the overall attrition rate of 34% was considerable, it is lower than many other recent antipsychotic drug trials. As these trials were short term, we could not comment on long term effects. The overall data were limited, hence no firm conclusions could be drawn.</P>
<P>1. Clinically important change in global and general mental state<BR/>One study (<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK>) suggested that zotepine may be as efficacious as the other three atypical antipsychotics such as clozapine, risperidone 4 mg, 8 mg and remoxipride. <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> suggested that zotepine may be less efficacious than clozapine. The result presented in <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> should be interpreted with caution, due to the limited data available in the abstract. This result confirmed the common notion that clozapine is the most effective antipsychotic drug available (<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>), although replication is needed.</P>
<P>2. Leaving the study early<BR/>
<LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> appears to have had no loss to follow up, but this is not explicitly described. Only <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> reported the number of participants leaving the study early for any reason but found no significant difference between the groups. Leaving the study early for any reason can be interpreted as a measure of acceptability of treatment. Nevertheless, the study was too small for any interpretation of relative acceptability of both the compounds. It was disappointing that specific reasons for leaving the study early had not been presented.</P>
<P>3. Adverse effects<BR/>The movement disorders associated with zotepine are comparable to clozapine, remoxipride and risperidone. The need for antiparkinson medication is similar to risperidone and remoxipride, but may be associated with increased need than necessary with clozapine. The result that more antiparkinson medication may be needed than with clozapine, should be approached with caution, as biperiden co-medication has been permitted in <LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK>. The frequency of biperiden administration appears to be dependent on the preparation, and the criteria for using biperiden has not been made clear. Zotepine may be associated with higher prolactin levels than clozapine. Zotepine, clozapine, risperidone, remoxipride are known to induce many adverse effects, but in the absence of data it is impossible to evaluate their relative tolerability.</P>
<P>4. Missing outcomes<BR/>There is no information available on other important outcomes such as service use, adverse events other than movement disorders, prolactin increase, quality of life or satisfaction with care.</P>
<P>5. Summary<BR/>To date, zotepine has been compared with only three atypical second generation antipsychotic medications, in three short term trials (n=289). Two studies compared zotepine with clozapine. One study compared zotepine with risperidone, clozapine and remoxipride. Two of these trials were poorly reported. One study has been published only as an abstract, and the other presented usable data on only one outcome. Zotepine may be as effective as risperidone and remoxipride. The evidence base is insufficient to provide firm conclusions as to whether zotepine is as effective or less effective, than clozapine. The movement disorders and the cognitive changes appear to be similar to the other three atypicals clozapine, risperidone and remoxipride. The use of antiparkinson medication is comparable to risperidone and remoxipride, but may be associated with increased need than necessary with clozapine. Zotepine may be associated with higher prolactin levels than clozapine. The cognitive changes on the short syndrome test were comparable to the other three atypicals. There are no other data on other adverse events or other important outcomes. The results should be considered with caution due to high risk of bias.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-09-08 10:03:35 +0100" MODIFIED_BY="[Empty name]">
<P>The three included studies reported only on eight outcomes. Important information on outcomes relevant to clinicians, consumers and policy makers (such as service use, other adverse events, quality of life or satisfaction with care) are not available. The studies were only short term which can be a problem in addressing the management of a typically chronic disorder such as schizophrenia. Furthermore, we could not identify any study which compared zotepine with any other atypical drugs. We feel the evidence to be woefully incomplete and the applicability of results very limited.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-08-03 15:24:10 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of the evidence is low. <LINK REF="STD-Klieser-1991" TYPE="STUDY">Klieser 1991</LINK> is not a well reported study with limited outcomes and not making explicit numbers leaving early or any data from the laboratory investigations. To date <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> has been presented only as an abstract. Details of the randomisation process and allocation concealment have not been reported and the study was only single-blind. It provided only limited data on efficacy and movement disorders and simple data such as the number of participants leaving the study early has not been presented. The allocation process of <LINK REF="STD-Meyer_x002d_Lindenberg-1997" TYPE="STUDY">Meyer-Lindenberg 1997</LINK> was not described either and the only usable outcome was leaving the study early. Other outcomes could not be analysed because they have only been reported for a matched (i.e. no longer randomised) sub-sample (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-05-12 21:27:37 +0100" MODIFIED_BY="[Empty name]">
<P>There are always means by which bias could be operating. We could have failed to identify relevant studies. Also, we did change the protocol text in this version of the review. The reason for this was to improve clarity of method for this and future versions of the review. This did not change how we handled any studies or outcomes in this version.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-08-03 15:25:03 +0100" MODIFIED_BY="[Empty name]">
<P>A Cochrane review had previously concluded that there were no clear differences between zotepine and other second generation antipsychotic drugs (<LINK REF="REF-DeSilva-2006" TYPE="REFERENCE">DeSilva 2006</LINK>). This statement is compatible with our finding that zotepine may be as effective [or ineffective] as risperidone and remoxipride.</P>
<P>The evidence-base is insufficient to provide firm conclusions as to whether zotepine is as effective or less effective, than clozapine. The previous version of this review (<LINK REF="REF-Komossa-2010" TYPE="REFERENCE">Komossa 2010</LINK>) concluded that zotepine may be less effective than clozapine. This was based mainly on one abstract (<LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>) with limited data. We have included <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> study in our current update. We have reached the current conclusions by including another study which compared different atypical antipsychotics and involving larger number of participants.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-08-03 15:25:20 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-08-03 15:25:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. For people with schizophrenia<BR/>There are three, only short term trials that have compared zotepine with clozapine, risperidone and remoxipride. Zotepine may be as effective as risperidone and remoxipride, and much the same applies to zotepine and clozapine. The movement disorders and cognitive changes appear to be similar to the three atypical antipsychotics clozapine, risperidone and remoxipride. The need for antiparkinson medication is similar to risperidone and remoxipride, but use of clozapine may be associated with increased need than is necessary with clozapine. Zotepine may be associated with higher prolactin levels than clozapine. There are no other data on other adverse events or other important outcomes. The evidence base is small and also prone to bias, making practical recommendations difficult.</P>
<P>2. For clinicians<BR/>Other than the comparison presented here, there are hardly any randomised controlled studies available comparing zotepine with other second generation antipsychotic drugs such as amisulpride, aripiprazole, olanzapine, quetiapine, sertindole, ziprasidone. More studies are needed to examine the relative efficacy and effects of zotepine with other second generation antipsychotic drugs and until that happens use of zotepine in comparison to other newer generation drugs is not based on good evidence.</P>
<P>3. For managers/policy makers<BR/>Only three small studies on zotepine versus clozapine, risperidone and remoxipride are available. The data relevant for policy makers such as service utilisation or functioning in society do not seem to exist. We are unable to make any particular recommendations for managers or policy makers except that better data does exist from comparisons of other newer antipsychotics and therefore they may be recommended before zotepine.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-05-17 12:21:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>We stress that strict adherence to the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) would improve the quality of reporting of future studies.</P>
<P>2. Specific<BR/>Currently only three short term trials comparing zotepine with clozapine, risperidone and remoxipride are available. There is, therefore, plenty of room for more research. Importantly, future studies should compare zotepine with second generation antipsychotic drugs other than clozapine and should be of longer duration and address real-world effectiveness, in addition to pure efficacy and tolerability (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-05-11 16:47:46 +0100" MODIFIED_BY="[Empty name]">
<P>We thank the editorial team of the Cochrane Schizophrenia Group for its assistance. We also fully acknowledge use of common 'template' text supplied by the editorial base of the Cochrane Schizophrenia Group for the methods sections which we have adapted for use in this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-05-17 12:22:16 +0100" MODIFIED_BY="[Empty name]">
<P>Selvizhi Subramanian - none.<BR/>Katja Komossa - none.<BR/>Stefan Leucht - has received speaker/consultancy honoria from Sanofi-Aventis, BMS, Eli Lilly, Janssen, Lundbeck and Pfizer. He received research support from Sanofi-Aventis and Eli Lilly.<BR/>Christine Rummel - has received lecture honoraria and travel grants to attend scientific meetings from AstraZeneca, Janssen-Cilag, Eli Lilly and Pfizer.<BR/>Werner Kissling - has received speaker or consultancy honoraria from Sanofi-Aventis, BMS, Lilly, Janssen, Lundbeck, Bayer and Pfizer.<BR/>Heike Hunger - none.<BR/>Franziska Schmidt - none<BR/>Sandra Schwarz - none.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-05-17 11:32:30 +0100" MODIFIED_BY="[Empty name]">
<P>Selvizhi Subramanian - updated review (2010), sought new trials, re-extracted data from included and excluded studies, updated text where necessary.<BR/>Katja Komossa - protocol development, searching, study selection, data extraction, report writing. <BR/>Christine Rummel - protocol development, searching, study selection, data extraction. <BR/>Stefan Leucht - protocol development, searching, study selection, data extraction, report writing. <BR/>Werner Kissling - protocol development. <BR/>Heike Hunger - helped with data extraction and writing. <BR/>Franziska Schmid - helped with data extraction and writing. <BR/>Sandra Schwarz - helped with data extraction and writing. <BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-08-03 15:27:17 +0100" MODIFIED_BY="[Empty name]">
<P>The review was slightly adapted to new functions available in Review Manager 5 but also refinements of text within the methods section. Although the text has changed and improved, we do not feel that this has made any impact on the results.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-09-08 13:56:44 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-08-03 11:48:18 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-08-03 11:21:40 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Klieser-1991" MODIFIED="2010-08-03 11:20:31 +0100" MODIFIED_BY="[Empty name]" NAME="Klieser 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-08-03 11:20:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klieser E, Lehmann E, Tegeler J</AU>
<TI>Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients</TI>
<TO>Doppelblindvergleich von 3 x 75 mg Zotepin und 3 x 4 mg Haloperidol bei akut schizophrenen Patienten</TO>
<SO>Fortschritte der Neurologie und Psychiatrie</SO>
<YR>1991</YR>
<VL>59</VL>
<NO>Suppl 1</NO>
<PG>14-7</PG>
<IDENTIFIERS MODIFIED="2010-08-03 11:20:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-03 11:20:31 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1683333"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2003" MODIFIED="2010-04-07 17:37:05 +0100" MODIFIED_BY="[Empty name]" NAME="Lin 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-24 21:07:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chiu H-J, Lin C-C, Bai Y-M, Chen J-Y, Wang Y-C, Lai I-C</AU>
<TI>A randomized, single-blind study to evaluate the antipsychotic effect and safety of clozapine versus switching to zotepine in schizophrenic patients</TI>
<SO>Proceedings of the12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2008-12-17 12:59:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 12:59:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lin C-C, Bai Y-M, Chen J-Y, Wang Y-C, Liou Y-J, Chao C-H, Lai I-C, Tsai K-Y, Chiu H-J</AU>
<TI>Switching from clozapine to zotepine in schizophrenic patients: a randomized, single-blind controlled study</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S318</PG>
<IDENTIFIERS MODIFIED="2008-12-17 12:59:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer_x002d_Lindenberg-1997" MODIFIED="2010-08-03 11:21:40 +0100" MODIFIED_BY="[Empty name]" NAME="Meyer-Lindenberg 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-08-03 11:21:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallhofer B, Gruppe H, Bauer U</AU>
<TI>Zotepine versus clozapine: a comparison of the impact on the cognitive dysfunction syndrome in schizophrenia (a double blind trial)</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1995</YR>
<VL>28</VL>
<PG>179</PG>
<IDENTIFIERS MODIFIED="2010-08-03 11:21:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-03 11:21:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9131723"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 12:59:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer-Lindenberg A, Bauer U, Lis S, Krieger S, Gallhofer B</AU>
<TI>Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: Results from a double-blind study</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>2</NO>
<PG>35-42</PG>
<IDENTIFIERS MODIFIED="2008-12-17 12:59:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-08-03 11:48:18 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Briken-2002" MODIFIED="2010-08-03 11:22:25 +0100" MODIFIED_BY="[Empty name]" NAME="Briken 2002" YEAR="1997">
<REFERENCE MODIFIED="2010-08-03 11:22:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Briken P, Nika E, Moritz S, Haasen C, Perro C, Yagdiran O, Naber D, Krausz M</AU>
<TI>Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>2-3</NO>
<PG>311-3</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2010-08-03 11:22:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-03 11:22:25 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12223264"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2006" MODIFIED="2010-08-03 11:22:34 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-08-03 11:22:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen JY, Chen TT, Lin CC, Bai YM, Wu BJ, Hung CH</AU>
<TI>Switching from other second generation antipsychotics to zotepine in schizophrenic patients: a 12-week open-label study</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S416</PG>
<IDENTIFIERS MODIFIED="2010-08-03 11:22:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hada-1985" MODIFIED="2010-08-03 11:22:57 +0100" MODIFIED_BY="[Empty name]" NAME="Hada 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-08-03 11:22:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hada Y</AU>
<TI>Clinical effects of zotepine in outpatients with schizophrenia</TI>
<SO>Shinryo to Shinyaku</SO>
<YR>1985</YR>
<VL>22</VL>
<NO>2</NO>
<PG>435-44</PG>
<IDENTIFIERS MODIFIED="2010-08-03 11:22:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-03 11:22:57 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10923750"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hen-1987" MODIFIED="2010-08-03 11:23:22 +0100" MODIFIED_BY="[Empty name]" NAME="Hen 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-08-03 11:23:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hen LS</AU>
<TI>Controlled clinical trial of zotepine in schizophrenia</TI>
<SO>Chinese Journal of Nervous and Mental Disorders</SO>
<YR>1987</YR>
<VL>1392</VL>
<PG>87-90</PG>
<IDENTIFIERS MODIFIED="2010-08-03 11:23:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-03 11:23:22 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1683336"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komada-1987" MODIFIED="2010-08-03 11:23:56 +0100" MODIFIED_BY="[Empty name]" NAME="Komada 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-08-03 11:23:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Komada A, Kishimoto A, Tanaka K, Fukuma E, Kunimoto N</AU>
<TI>Effects of zotepine in acute treatment and maintenance therapy of schizophrenic out-patients</TI>
<SO>Igaku to Yakugaku</SO>
<YR>1987</YR>
<VL>18</VL>
<NO>4</NO>
<PG>1175-87</PG>
<IDENTIFIERS MODIFIED="2010-08-03 11:23:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-03 11:23:56 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10923750"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2005" MODIFIED="2010-04-12 15:24:36 +0100" MODIFIED_BY="[Empty name]" NAME="Lin 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-12 15:24:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin CC, Chen JY, Bai YM, Wang YC, Liou YJ, Lin WK, Chen TT</AU>
<TI>Long-term outcome of switching from clozapine to zotepine in refractory schizophrenia: a 2-year follow-up study</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>S500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohhara-1988" MODIFIED="2010-08-03 11:48:18 +0100" MODIFIED_BY="[Empty name]" NAME="Ohhara 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-08-03 11:48:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohhara K, Suzuki Y, Kawaguchi K</AU>
<TI>Effects of zotepine on chronic schizophrenics with a mean disease duration of 19.9 years</TI>
<SO>Shinryo to Shinyaku</SO>
<YR>1988</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1205-11</PG>
<IDENTIFIERS MODIFIED="2010-08-03 11:24:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Perro-1999" MODIFIED="2010-05-11 17:22:34 +0100" MODIFIED_BY="[Empty name]" NAME="Perro 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-03-24 14:02:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Perro C, Naber D, Lambert M, Moritz S, Krause M</AU>
<TI>A prospective clinical comparative-study of four atypical antipsychotic agents in the treatment of schizophrenia</TI>
<SO>Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-1987" MODIFIED="2010-08-03 11:27:34 +0100" MODIFIED_BY="[Empty name]" NAME="Saletu 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-08-03 11:27:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu B, Grunberger J, Linzmayer L, Anderer P</AU>
<TI>Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1987</YR>
<VL>20</VL>
<NO>Suppl 1</NO>
<PG>12-27</PG>
<IDENTIFIERS MODIFIED="2010-08-03 11:27:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-03 11:27:34 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2883677"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takashina-1986" MODIFIED="2010-08-03 11:28:22 +0100" MODIFIED_BY="[Empty name]" NAME="Takashina 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-08-03 11:28:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takashina K, Yasuda T, Terada H, Yoshida H, Okuda J</AU>
<TI>Clinical use of zotepine (lodopin) for schizophrenia and mania</TI>
<SO>Shinryo to Shinyaku</SO>
<YR>1986</YR>
<VL>23</VL>
<NO>9</NO>
<PG>2043-69</PG>
<IDENTIFIERS MODIFIED="2010-08-03 11:28:22 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-04-22 15:10:47 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2010-08-03 11:28:39 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Tsai-2007" MODIFIED="2010-08-03 11:28:39 +0100" MODIFIED_BY="[Empty name]" NAME="Tsai 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-08-03 11:28:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Tsai C-J</AU>
<TI>A multi-centre comparative study to evaluate the anti-aggression effect and safety of zotepine versus risperidone in aggressive schizophrenic patients in an acute ward</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS MODIFIED="2010-08-03 11:28:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-09-08 13:56:44 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-09-08 13:56:44 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2010-08-03 11:33:41 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<NO>7066</NO>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2010-08-03 11:33:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-03 11:33:41 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8916759"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-APA-2004" MODIFIED="2010-08-03 11:34:45 +0100" MODIFIED_BY="[Empty name]" NAME="APA 2004" TYPE="BOOK">
<AU>Work Group on Schizophrenia</AU>
<SO>Treatment of patients with schizophrenia</SO>
<YR>2004</YR>
<EN>2nd</EN>
<PB>American Psychiatric Association</PB>
<IDENTIFIERS MODIFIED="2010-08-03 11:34:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-03 11:34:27 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1176/appi.books.9780890423363.45859"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arnt-1998" MODIFIED="2010-05-11 16:24:17 +0100" MODIFIED_BY="[Empty name]" NAME="Arnt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Arnt J, Skarsfeldt T</AU>
<TI>Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>63-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2009-07-24 21:19:38 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeSilva-2006" MODIFIED="2008-11-10 09:49:34 +0000" MODIFIED_BY="[Empty name]" NAME="DeSilva 2006" TYPE="COCHRANE_REVIEW">
<AU>DeSilva P, Fenton M, Rathbone J</AU>
<TI>Zotepine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-11-10 09:49:34 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-10 09:49:34 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001948.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2005" MODIFIED="2009-07-24 21:21:42 +0100" MODIFIED_BY="[Empty name]" NAME="Duggan 2005" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-24 21:21:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-24 21:21:42 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-05-12 12:40:04 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Sayeh-2006" MODIFIED="2009-07-24 21:18:26 +0100" MODIFIED_BY="[Empty name]" NAME="El-Sayeh 2006" TYPE="COCHRANE_REVIEW">
<AU>El-Sayeh HG, Morganti C</AU>
<TI>Aripiprazole for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-24 21:18:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-24 21:18:26 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004578.pub3 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2010-05-12 12:43:56 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erzigkeit-1989" MODIFIED="2010-09-08 13:56:39 +0100" MODIFIED_BY="[Empty name]" NAME="Erzigkeit 1989" TYPE="BOOK_SECTION">
<AU>Erzigkeit H</AU>
<TI>A short cognitive performance test as an instrument for the assessment of clinical efficacy of cognitive enhancers</TI>
<SO>Diagnosis and Treatment of Senile Dementia</SO>
<YR>1989</YR>
<PG>164</PG>
<ED>Bergener M, Reisberg B</ED>
<PB>Springer-Verlag</PB>
<CY>Berlin</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaebel-2006" MODIFIED="2009-07-24 21:25:32 +0100" MODIFIED_BY="[Empty name]" NAME="Gaebel 2006" TYPE="BOOK">
<AU>Gaebel W, Falkai P, Weinmann S, Wobrock T</AU>
<TO>Behandlungsleitlinie Schizophrenie</TO>
<SO>Treatment guidelines for schizophrenia</SO>
<YR>2006</YR>
<PB>Steinkopf</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heres-2006" NAME="Heres 2006" TYPE="JOURNAL_ARTICLE">
<AU>Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S</AU>
<TI>Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>185-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-07-24 21:26:42 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]</TI>
<SO>The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2006" NAME="Jones 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW</AU>
<TI>Randomized controlled trial of the effect on quality of life</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<PG>1079-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1988" MODIFIED="2009-01-30 17:47:09 +0000" MODIFIED_BY="[Empty name]" NAME="Kane 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group</AU>
<TI>Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>789-96</PG>
<IDENTIFIERS MODIFIED="2009-01-30 17:47:09 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1993" NAME="Kane 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Treatment programme and long term outcome in chronic schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>46</VL>
<PG>585-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2009-07-24 21:35:52 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and negative syndrome scale (PANSS) manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda (NY)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005" MODIFIED="2010-08-03 11:36:26 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2010-08-03 11:36:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-03 11:36:26 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16199797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leysen-1993" NAME="Leysen 1993" TYPE="JOURNAL_ARTICLE">
<AU>Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP</AU>
<TI>Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors</TI>
<SO>Psychopharmacology</SO>
<YR>1993</YR>
<VL>112</VL>
<PG>40-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lieberman-2005" MODIFIED="2008-12-10 23:19:14 +0000" MODIFIED_BY="[Empty name]" NAME="Lieberman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Liebermann JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>1209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marvaha-2004" MODIFIED="2009-07-22 15:52:45 +0100" MODIFIED_BY="[Empty name]" NAME="Marvaha 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marvaha S, Johnson S</AU>
<TI>Schizophrenia and employment - a review</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>337-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2009-07-24 21:29:47 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-M_x00f6_ller-2000" NAME="Möller 2000" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ</AU>
<TI>New assessment of atypical antipsychotics</TI>
<TO>Aktuelle Bewertung neuer/atypischer Neuroleptika</TO>
<SO>Nervenarzt</SO>
<YR>2000</YR>
<VL>71</VL>
<PG>329-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Needham-1996" NAME="Needham 1996" TYPE="JOURNAL_ARTICLE">
<AU>Needham PL, Atkinson J, Skill MJ, Heal DJ</AU>
<TI>Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1996</YR>
<VL>32</VL>
<PG>123-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roth-1994" NAME="Roth 1994" TYPE="JOURNAL_ARTICLE">
<AU>Roth BL, Craigo SC, Choudhar MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR,</AU>
<TI>Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1994</YR>
<VL>268</VL>
<PG>1403-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rust-1989" MODIFIED="2010-05-11 16:40:39 +0100" MODIFIED_BY="[Empty name]" NAME="Rust 1989" TYPE="BOOK">
<AU>Rust J, Golombok S</AU>
<SO>Modern Psychometrics</SO>
<YR>1989</YR>
<PB>Routledge</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2010-09-08 13:53:09 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JW</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica Scandanivia Suppl</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tandon-2008" MODIFIED="2009-07-24 21:30:22 +0100" MODIFIED_BY="[Empty name]" NAME="Tandon 2008" TYPE="JOURNAL_ARTICLE">
<AU>Tandon R, Keshavan MS, Nasralllah HA</AU>
<TI>Schizophrenia, "Just the facts" What we know in 2008. 2. Epidemiology and etiology</TI>
<SO>Schizophrenia research</SO>
<YR>2008</YR>
<VL>102</VL>
<PG>1-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsuang-1978" MODIFIED="2009-07-22 15:52:45 +0100" MODIFIED_BY="[Empty name]" NAME="Tsuang 1978" TYPE="JOURNAL_ARTICLE">
<AU>Tsuang MT</AU>
<TI>Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>153-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2009-01-30 17:47:27 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>3-92</PG>
<IDENTIFIERS MODIFIED="2009-01-30 17:47:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001" MODIFIED="2009-07-24 21:34:35 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2001" TYPE="OTHER">
<AU>WHO</AU>
<TI>Mental Health: New Understanding, New Hope</TI>
<SO>The World Health report</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2007" MODIFIED="2010-08-03 11:41:28 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2007" TYPE="CONFERENCE_PROC">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, Pinfold V, Takriti Y</AU>
<TI>The Leeds Outcomes Stakeholders Survey (LOSS) Study</TI>
<SO>Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo</SO>
<YR>2007</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-08-03 11:40:25 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Komossa-2010" MODIFIED="2010-08-03 11:40:25 +0100" MODIFIED_BY="[Empty name]" NAME="Komossa 2010" TYPE="COCHRANE_REVIEW">
<AU>Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Kissling W, Leucht S</AU>
<TI>Zotepine versus other atypical antipsychotics for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<PG>CD006628</PG>
<IDENTIFIERS MODIFIED="2010-08-03 11:40:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-22 16:05:54 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858"/>
<IDENTIFIER MODIFIED="2010-08-03 11:40:25 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20091601"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2008" MODIFIED="2009-07-24 21:33:25 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2008" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H,schmid F, Asenjo Lobos C, Schwarz S, Davis JM</AU>
<TI>A meta-Analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>166</VL>
<NO>2</NO>
<PG>152-63</PG>
<IDENTIFIERS MODIFIED="2009-07-24 21:33:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-24 21:33:25 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1176/appi.ajp.2008.08030368"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-05-11 16:43:57 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-08-03 15:31:01 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-08-03 15:29:26 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-08-03 15:28:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klieser-1991">
<CHAR_METHODS MODIFIED="2010-03-30 13:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 4 weeks.<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-03 15:28:21 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: paranoid hallucinatory schizophrenia (ICD 9).<BR/>N=180.<BR/>Age:18-65 years.<BR/>Sex: 44M, 53F.<BR/>Setting:Unclear.<BR/>History: acutely ill, duration ill 2-4months.<BR/>Excluded: depot neuroleptic treatment in the preceding 4 weeks, age other than 18-65 years, pregnancy, severe physical disease, allergies, psychoses other than schizophrenia, other history or present impairment of brain functioning, drug addiction or intoxication, anamnestic hyperthermia to anaesthetics or neuroleptics.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-03 15:28:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Zotepine: fixed dose, 225 mg/day. N=20.<BR/>2. Clozapine: fixed dose 400 mg. N=37.<BR/>3. Risperidone: fixed dose, 4 mg. N=20.<BR/>4. Risperidone: fixed dose, 8 mg. N =20.<BR/>5. Remoxipride: fixed dose, 400 mg. N=38.<BR/>6. Haloperidol: fixed dose, 15 mg. N=45.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-27 17:24:47 +0000" MODIFIED_BY="[Empty name]">
<P>Mental state: BPRS.<BR/>Cognitive functioning: Short syndrome test (SKT).<BR/>Adverse effects: CGI, EPS (Simpson &amp; Angus), use of anticholinergic medication.<BR/>
</P>
<P>Unable to use -<BR/>Laboratory measures: EEG, ECG, blood pressure, pulse rate (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:19:47 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-17 12:25:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2003">
<CHAR_METHODS MODIFIED="2010-05-17 12:24:09 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blind.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-17 12:25:07 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=59.<BR/>Age: 20-65 years.<BR/>Sex: not described.<BR/>Setting: inpatient.<BR/>History: BPRS &gt;30, clozapine treatment for more than 5 months.<BR/>Excluded: not described.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-08 21:36:53 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose, mean ~ 387 mg/day. N=24.<BR/>2. Zotepine: flexible dose, mean ~ 377 mg/day. N=35.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-17 11:26:57 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: BPRS total score.<BR/>Adverse effects: use of antiparkinson medication, laboratory (prolactin).</P>
<P>Unable to use -<BR/>Global state: CGI (no data).<BR/>Adverse effects: BAS, SAS, UKU, weight, laboratory - haematology, biochemistry, urine analysis (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-17 12:25:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyer_x002d_Lindenberg-1997">
<CHAR_METHODS MODIFIED="2009-07-22 17:01:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-17 12:25:39 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia catatonic, hebephrenic, paranoid or residual (DSM -III -R).<BR/>N=50.<BR/>Age: 18-60 years.<BR/>Sex:<B> </B>18M, 8F.<BR/>Setting: unclear.<BR/>History: BPRS &gt;40 after washout phase, no previous treatment with either medication.<BR/>Excluded: former treatment with clozapine or zotepine.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-17 12:25:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose, allowed range 150-450 mg/day. N=25.<BR/>2. Zotepine: flexible dose, allowed range 150-450 mg/day. N=25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-17 11:26:58 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.</P>
<P>Unable to use -<BR/>Global state: CGI (no data).<BR/>Mental state: BPRS, SANS (reported for a no longer randomised sub -sample, no usable data).<BR/>General functioning: NOSIE, Cognitive Functioning: maze tests (reported for a no longer randomised sub -sample, no usable data).<BR/>Adverse events: UKU, ECG, weight gain (reported for a no longer randomised sub -sample, no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-17 12:55:44 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Diagnostic tool<BR/>DSM III-R and DSM-IV - Diagnostic Statistical Manual version 3 Revised and version 4.<BR/>ICD 10 - The International Statistical Classification of Diseases and Related Health Problems.<BR/>
</P>
<P>Rating Scales</P>
<P>Global rating scales<BR/>CGI - Clinical Global Impressions.<BR/>CGI-S - Clinical Global Impression-Severity.<BR/>CGI-I - Clinical Global Impression-Improvement.<BR/>
</P>
<P>Mental state<BR/>BPRS - Brief Psychiatric Rating Scale.<BR/>PANSS - Positive and Negative Syndrome Scale.<BR/>SANS - Scale for the Assessment of Negative Symptoms.</P>
<P>Side effects<BR/>AIMS - Abnormal Involuntary Movement Scale.<BR/>BAS - Barnes Akathisia Scale.<BR/>ESRS - Extrapyramidal Syndrome Rating Scale.<BR/>SAS - Simpson-Angus Index - for neurological side effects.<BR/>UKU - Udvalg for kliniske ndersogelser Side Effect Rating Scale.</P>
<P>Quality of Life<BR/>QLS - Quality of Life Scale.<BR/>SWN -Subjective Well-being List.<BR/>
<BR/>General functioning:<BR/>NOSIE - Nurses´observation scale for inpatient evaluation<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-05-17 11:26:59 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-05-17 11:26:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Briken-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-17 11:26:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia (number unclear).<BR/>Interventions: zotepine vs risperidone vs olanzapine.<BR/>Outcomes: PANSS, UKU, PANSS -EC, but no data available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-24 13:59:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-24 13:59:56 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, open label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-24 14:03:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hada-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-24 14:03:20 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, diagnostic study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-17 16:06:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hen-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-17 16:06:07 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, diagnostic study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-17 16:06:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Komada-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-17 16:06:27 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 15:44:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 15:44:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, naturalistic study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-24 14:03:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ohhara-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-24 14:03:56 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-17 11:26:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perro-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-17 11:26:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia (number = 75).<BR/>Interventions: zotepine vs risperidone vs olanzapine vs sertindole.
<BR/>
Outcomes: PANSS, CGI, GAF, UKU, BDI, SCL -R 90, QLS scales but no data available on any of them (PANSS, CGI, GAF, UKU, BDI, SCL -R 90, QLS scales).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-26 18:21:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saletu-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-26 18:21:44 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, but placebo controlled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-24 14:04:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takashina-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-24 14:04:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-04-22 15:10:47 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-08-03 15:31:01 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-08-03 15:31:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsai-2007">
<CHAR_STUDY_NAME MODIFIED="2010-08-03 15:31:01 +0100" MODIFIED_BY="[Empty name]">
<P>A multi centre comparative study to evaluate the anti -aggression effect and safety of zotepine versus risperidone in aggressive schizophrenic patients in an acute ward.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-03-27 18:10:31 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: open label.<BR/>Duration: unknown.<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-11 17:26:33 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=160.<BR/>Age: adults.<BR/>Sex: mixed gender.<BR/>History: aggression.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-11 17:25:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Zotepine.<BR/>2. Risperidone.<BR/>3. Active control.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-17 12:28:55 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS-EC, PANSS.<BR/>Global outcome: CGI.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-03-27 18:10:31 +0000" MODIFIED_BY="[Empty name]">
<P>17/01/2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-05-11 17:26:00 +0100" MODIFIED_BY="[Empty name]">
<P>Astellas Pharma, Taiwan Inc.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-03-27 18:10:19 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-08-03 15:29:26 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-04-16 11:11:40 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 12:08:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1991">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-27 18:19:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2003">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-27 18:21:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyer_x002d_Lindenberg-1997">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-04-25 17:12:07 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 17:12:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1991">
<DESCRIPTION>
<P>No further details. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-27 18:19:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-27 18:21:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyer_x002d_Lindenberg-1997">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-04-16 11:11:40 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-12-15 19:20:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1991">
<DESCRIPTION>
<P>Double, no further details. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-27 18:19:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2003">
<DESCRIPTION>
<P>Single blind (blind raters). Whether the blinding strategy was successful has not been examined. There were no objective outcomes. Overall, it is unclear whether blinding was a concern.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-27 18:21:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyer_x002d_Lindenberg-1997">
<DESCRIPTION>
<P>Double, no further details, unclear whether successful.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-04-22 13:05:59 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 19:20:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klieser-1991">
<DESCRIPTION>
<P>Data on leaving early are missing. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-27 18:19:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lin-2003">
<DESCRIPTION>
<P>The number of participants leaving the study early has not been reported. Therefore, there was no attempt to address incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-22 13:05:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meyer_x002d_Lindenberg-1997">
<DESCRIPTION>
<P>Reasons for leaving early - not reported (overall attrition high - 34%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-05-17 12:26:11 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 21:30:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klieser-1991">
<DESCRIPTION>
<P>Data on laboratory measures were not presented. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-27 18:19:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lin-2003">
<DESCRIPTION>
<P>The study has only been published as an abstract in which only a few outcomes (global state, use of antiparkinson medication and mental state) have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-17 12:26:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meyer_x002d_Lindenberg-1997">
<DESCRIPTION>
<P>Apart from 'leaving the study' all other data reported for a no longer randomised sub-sample.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-08-03 15:29:26 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-17 12:24:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klieser-1991">
<DESCRIPTION>
<P>Biperiden co-medication was permitted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-03 15:29:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lin-2003">
<DESCRIPTION>
<P>The study used an "enriched design". All participants had been stable on clozapine before the study and were than randomised to either continuation of clozapine or switched to zotepine. This design can mean an advantage for clozapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 16:45:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meyer_x002d_Lindenberg-1997">
<DESCRIPTION>
<P>Sponsored by manufacturer of zotepine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-05-17 16:03:59 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-05-17 16:03:31 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2010-05-17 16:03:31 +0100" MODIFIED_BY="Grade Profiler">ZOTEPINE versus CLOZAPINE for schizophrenia (all short term outcomes)</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>ZOTEPINE versus CLOZAPINE for schizophrenia (all short term outcomes)</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> in hospital<BR/>
<B>Intervention:</B> ZOTEPINE versus CLOZAPINE - all short term outcomes<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ZOTEPINE versus CLOZAPINE - all short term outcomes</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: Average score (BPRS total, high=poor)</B>
<BR/>Brief Psychiatric Rating Scale. Scale from: 0 to 126.<BR/>Follow-up: 12 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Mental state: Average score (BPRS total, high=poor) in the intervention groups was<BR/>
<B>6 higher</B>
<BR/>(2.17 to 9.83 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>59<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Global state: No clinically important response (as defined by the original studies)</B>
<BR/>clinical assessment<BR/>Follow-up: 12 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 8.23 </B>
<BR/>(1.14 to 59.17)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>59<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>411 per 1000</B>
<BR/>(57 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>823 per 1000</B>
<BR/>(114 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(228 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: Extrapyramidal effects - use of antiparkinson medication</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 20.96 </B>
<BR/>(2.89 to 151.9)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>116<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>210 per 1000</B>
<BR/>(29 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(289 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(578 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Behaviour: No clinically important response (as defined by the original studies)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No trials reported on this outcome that we had pre-specified as being of importance.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in design - serious: randomisation stated not described, blinding not tested.<BR/>
<SUP>2</SUP> Indirectness: scale derived score, problematic to interpret.<BR/>
<SUP>3</SUP> Publication bias: likely as small trial with commercial interest. <BR/>
<SUP>4</SUP> Imprecission: considerable because of few events in one arm. Small study/studies.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2010-05-17 16:03:45 +0100" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2010-05-17 16:03:45 +0100" MODIFIED_BY="Grade Profiler">ZOTEPINE versus RISPERIDONE for schizophrenia (all short term outcomes)</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>ZOTEPINE versus RISPERIDONE for schizophrenia (all short term outcomes)</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> in hospital<BR/>
<B>Intervention:</B> ZOTEPINE versus RISPERIDONE - all short term outcomes<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ZOTEPINE versus RISPERIDONE - all short term outcomes</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: Average endpoint score (BPRS total, high=poor) - vs 4mg Risperidone</B>
<BR/>Scale from: 0 to 129.<BR/>Follow-up: 12 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Mental state: Average endpoint score (BPRS total, high=poor) - vs 4mg Risperidone in the intervention groups was<BR/>
<B>1.4 higher</B>
<BR/>(9.82 lower to 12.62 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: Average endpoint score (BPRS total, high=poor) - vs 8 mg Risperidone</B>
<BR/>Scale from: 0 to 129.<BR/>Follow-up: 12 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Mental state: Average endpoint score (BPRS total, high=poor) - vs 8 mg Risperidone in the intervention groups was<BR/>
<B>1.3 lower</B>
<BR/>(12.95 lower to 10.35 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state: No clinically important response (as defined by the original studies)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No trials reported on this outcome that we had pre-specified as being of importance.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: Extrapyramidal effects - use of antiparkinson medication - vs 4mg risperidone</B>
<BR/>Follow-up: 12 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 6 </B>
<BR/>(0.79 to 45.42)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
<BR/>(40 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(158 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(316 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: Extrapyramidal effects - use of antiparkinson medication - vs 8mg risperidone</B>
<BR/>Follow-up: 12 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 3 </B>
<BR/>(0.69 to 13.12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
<BR/>(34 to 656)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
<BR/>(138 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(276 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Behaviour: No clinically important response (as defined by the original studies)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No trials reported on this outcome that we had pre-specified as being of importance.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in design - serious: randomisation stated not described, blinding not tested.<BR/>
<SUP>2</SUP> Indirectness: scale derived score, problematic to interpret.<BR/>
<SUP>3</SUP> Imprecission: considerable because of few events in one arm. Small study/studies.<BR/>
<SUP>4</SUP> Publication bias: likely as small trial with commercial interest. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2010-05-17 16:03:59 +0100" MODIFIED_BY="Grade Profiler" NO="3" READONLY="YES">
<TITLE MODIFIED="2010-05-17 16:03:59 +0100" MODIFIED_BY="Grade Profiler">ZOTEPINE versus REMOXIPRIDE for schizophrenia (all short term outcomes)</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>ZOTEPINE versus REMOXIPRIDE for schizophrenia (all short term outcomes)</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> in hospital<BR/>
<B>Intervention:</B> ZOTEPINE versus REMOXIPRIDE - all short term outcomes<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ZOTEPINE versus REMOXIPRIDE - all short term outcomes</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: Average endpoint score (BPRS total, high=poor)</B>
<BR/>Scale from: 0 to 129.<BR/>Follow-up: 12 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Mental state: Average endpoint score (BPRS total, high=poor) in the intervention groups was<BR/>
<B>5.7 higher</B>
<BR/>(4.13 lower to 15.53 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>58<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state: No clinically important response (as defined by the original studies)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No trials reported on this outcome that we had pre-specified as being of importance.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: Extrapyramidal effects - use of antiparkinson medication</B>
<BR/>Follow-up: 12 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.97 </B>
<BR/>(0.41 to 2.29)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>49 per 1000</B>
<BR/>(20 to 114)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>194 per 1000</B>
<BR/>(82 to 458)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>388 per 1000</B>
<BR/>(164 to 916)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Behaviour: No clinically important response (as defined by the original studies)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No trials reported on this outcome that we had pre-specified as being of importance.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in design - serious: randomisation stated not described, blinding not tested.<BR/>
<SUP>2</SUP> Indirectness: scale derived score, problematic to interpret.<BR/>
<SUP>3</SUP> Imprecission: considerable because of few events in one arm. Small study/studies.<BR/>
<SUP>4</SUP> Publication bias: likely as small trial with commercial interest. </P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-05-17 12:29:37 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-05-17 12:29:37 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-12-08 21:44:14 +0000" MODIFIED_BY="[Empty name]">Suggested design of future study</TITLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Methods</P>
</TH>
<TD>
<P>Allocation: randomised - clearly described generation of sequence and concealment of allocation.<BR/>Blinding: double - described and tested.<BR/>Duration: 6 months minimum.</P>
</TD>
</TR>
<TR>
<TH>
<P>Participants</P>
</TH>
<TD>
<P>Diagnosis: schizophrenia (operational criteria).<BR/>N=2700.*<BR/>Age: any.<BR/>Sex: both.<BR/>History: any.</P>
</TD>
</TR>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TD>
<P>1. Zotepine: dose ~ 100-300 mg/day. N=300.<BR/>2. Amisulpride: dose ~ 400-800 mg/day. N=300.<BR/>3. Aripiprazole: dose ~ 10-30 mg/day. N=300.<BR/>4. Clozapine: dose ~ 300-800 mg/day. N=300.<BR/>5. Olanzapine: dose ~ 10-20 mg/day. N=300.<BR/>6. Quetiapine: dose ~300-800 mg/day. N=300.<BR/>7. Risperidone: dose ~ 4-8 mg/day. N=300.<BR/>8. Sertindole: dose ~ 12-24 mg/day. N=300.<BR/>9. Ziprasidone: dose ~ 120-160 mg/day. N=300.<BR/>
</P>
</TD>
</TR>
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TD>
<P>Leaving study early (any reason, adverse events, inefficacy).<BR/>Service outcomes: hospitalised, time in hospital, attending out patient clinics.<BR/>Global impression: CGI**, relapse.<BR/>Mental state: Target symptoms - CGI.<BR/>Adverse events: UKU.<BR/>Employment, family satisfaction, patient satisfaction.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<BR/>** Primary outcome<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-09-08 10:08:23 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-05-11 16:12:37 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>ZOTEPINE versus CLOZAPINE - all short term outcomes</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="59.16722521417677" CI_START="1.1443732152387387" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.228571428571428" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.7720812024960682" LOG_CI_START="0.05856768432184227" LOG_EFFECT_SIZE="0.9153244434089551" METHOD="MH" MODIFIED="2010-04-09 00:39:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.03626473322691314" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="24" WEIGHT="100.0" Z="2.0939466473100956">
<NAME>Global state: 1. No clinically important response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours zotepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="59.16722521417677" CI_START="1.1443732152387387" EFFECT_SIZE="8.228571428571428" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.7720812024960682" LOG_CI_START="0.05856768432184227" LOG_EFFECT_SIZE="0.9153244434089551" MODIFIED="2009-10-22 12:22:26 +0100" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="1.0065263226042516" STUDY_ID="STD-Lin-2003" TOTAL_1="35" TOTAL_2="24" VAR="1.013095238095238" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.150715076978177" CI_START="0.6477311583781613" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.4984091311679766" LOG_CI_START="-0.1886052111964903" LOG_EFFECT_SIZE="0.15490195998574316" METHOD="MH" MODIFIED="2010-04-08 21:38:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.37678749636000775" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.8838309304048203">
<NAME>Leaving the study early - any reason</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours zotepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.150715076978177" CI_START="0.6477311583781613" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.4984091311679766" LOG_CI_START="-0.1886052111964903" LOG_EFFECT_SIZE="0.15490195998574316" MODIFIED="2009-10-22 12:22:49 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.40355562548072954" STUDY_ID="STD-Meyer_x002d_Lindenberg-1997" TOTAL_1="25" TOTAL_2="25" VAR="0.16285714285714284" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.82886949560699" CI_START="2.171130504393011" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2010-04-08 21:40:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.002130958903581936" Q="0.0" RANDOM="YES" SCALE="631.034991757347" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="3.0713462343735625">
<NAME>Mental state: 1. Average score (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours zotepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.82886949560699" CI_START="2.1711305043930107" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="-1.3" MODIFIED="2009-10-22 12:24:19 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="8.7" SD_2="6.3" SE="1.9535407414669979" STUDY_ID="STD-Lin-2003" TOTAL_1="35" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="12.167191227766887" CI_START="-7.767191227766881" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.200000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2010-04-26 18:07:49 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6652970916489143" Q="0.0" RANDOM="YES" SCALE="54.151550027552" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="0.43261142155834775">
<NAME>Mental state: 2. Average endpoint score (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.167191227766887" CI_START="-7.767191227766881" EFFECT_SIZE="2.200000000000003" ESTIMABLE="YES" MEAN_1="40.6" MEAN_2="38.4" MODIFIED="2010-03-27 16:53:07 +0000" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="18.6" SD_2="17.8" SE="5.085395092148027" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="37" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.445027105394523" CI_START="-0.24502710539452233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2010-05-11 16:12:37 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.07923000454354877" Q="0.0" RANDOM="YES" SCALE="6.172914799769291" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="1.7551713402654507">
<NAME>Adverse effects: 1a. Extrapyramidal effects - average end point EPS score (high=poor)</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.445027105394523" CI_START="-0.24502710539452233" EFFECT_SIZE="2.1" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="0.5" MODIFIED="2010-04-08 21:20:14 +0100" MODIFIED_BY="[Empty name]" ORDER="18" SD_1="5.3" SD_2="1.0" SE="1.1964643860253539" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="37" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.012978024767954519" CI_END="151.89821594829925" CI_START="2.8918889559979393" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="20.958835204673868" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="2.1815526730835955" LOG_CI_START="0.46118161271542923" LOG_EFFECT_SIZE="1.3213671428995124" METHOD="MH" MODIFIED="2010-05-11 16:12:19 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9093003140183091" P_Q="0.0" P_Z="0.0026057496144707335" Q="0.0" RANDOM="YES" SCALE="673.2033981746009" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="61" WEIGHT="100.0" Z="3.010783045703409">
<NAME>Adverse effects: 1b. Extrapyramidal effects - use of antiparkinson medication</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours zotepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="397.2846700323493" CI_START="1.3928793539086546" EFFECT_SIZE="23.523809523809526" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.5991018073186223" LOG_CI_START="0.14391350106083317" LOG_EFFECT_SIZE="1.3715076541897278" MODIFIED="2010-04-26 17:43:16 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="1.4421897644739483" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="37" VAR="2.0799113167534222" WEIGHT="49.09922564602409"/>
<DICH_DATA CI_END="301.0754817370274" CI_START="1.1676889063556166" EFFECT_SIZE="18.75" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.4786753899203577" LOG_CI_START="0.06732715420711774" LOG_EFFECT_SIZE="1.2730012720637376" MODIFIED="2010-04-26 17:43:17 +0100" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="1.4164378900242311" STUDY_ID="STD-Lin-2003" TOTAL_1="35" TOTAL_2="24" VAR="2.0062962962962962" WEIGHT="50.900774353975905"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="51.93357925369992" CI_START="14.866420746300076" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="33.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2010-04-26 18:09:25 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="4.1224466735662166E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="3.5321184422900527">
<NAME>Adverse effects: 2. Prolactin - average change from baseline (in ng/ml)</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours zotepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="51.93357925369992" CI_START="14.866420746300076" EFFECT_SIZE="33.4" ESTIMABLE="YES" MEAN_1="34.4" MEAN_2="1.0" MODIFIED="2009-07-22 16:32:41 +0100" MODIFIED_BY="[Empty name]" ORDER="184" SD_1="35.68" SD_2="35.68" SE="9.456081540217285" STUDY_ID="STD-Lin-2003" TOTAL_1="35" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5163541610059825" CI_START="0.21368600883060782" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5692307692307692" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.1808006473429911" LOG_CI_START="-0.6702239124947122" LOG_EFFECT_SIZE="-0.24471163257586057" METHOD="MH" MODIFIED="2010-04-26 18:09:25 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.25966932906743123" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="37" WEIGHT="100.0" Z="1.127173078384844">
<NAME>Cognitive functioning: Not improved (SKT)</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5163541610059825" CI_START="0.21368600883060782" EFFECT_SIZE="0.5692307692307692" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="0.1808006473429911" LOG_CI_START="-0.6702239124947122" LOG_EFFECT_SIZE="-0.24471163257586057" MODIFIED="2010-03-27 17:34:32 +0000" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.4998960390881787" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="37" VAR="0.2498960498960499" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-08-03 15:18:33 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>ZOTEPINE versus RISPERIDONE - all short term outcomes</NAME>
<CONT_OUTCOME CHI2="0.10699503918748315" CI_END="8.184139346959864" CI_START="-7.982612943108627" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10076320192561775" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-08-03 15:18:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7435915590560287" P_Q="0.7435915590560287" P_Z="0.9805081024945616" Q="0.10699503918748315" RANDOM="YES" SCALE="13.713800220296397" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="0.024431901126173706">
<NAME>Mental state: Average endpoint score (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.62256962087015" CI_START="-9.822569620870153" DF="0" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" MODIFIED="2010-08-03 15:18:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8068414419870162" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.2445027895619612">
<NAME>vs 4 mg Risperidone</NAME>
<CONT_DATA CI_END="12.62256962087015" CI_START="-9.822569620870153" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" MEAN_1="40.6" MEAN_2="39.2" MODIFIED="2010-04-26 12:43:54 +0100" MODIFIED_BY="[Empty name]" ORDER="40" SD_1="18.6" SD_2="17.6" SE="5.725906041841762" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.352805945088765" CI_START="-12.952805945088759" DF="0" EFFECT_SIZE="-1.2999999999999972" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" MODIFIED="2010-04-26 12:43:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.826918210913896" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.21865576341944798">
<NAME>vs 8 mg Risperidone</NAME>
<CONT_DATA CI_END="10.352805945088765" CI_START="-12.952805945088759" EFFECT_SIZE="-1.2999999999999972" ESTIMABLE="YES" MEAN_1="40.6" MEAN_2="41.9" MODIFIED="2010-04-26 12:43:52 +0100" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="18.6" SD_2="19.0" SE="5.9454184041158955" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.15116458429739316" CI_END="3.8971517349676636" CI_START="0.3718595252513708" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.1345056301095173" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2010-08-03 15:17:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6974250760773741" P_Q="0.6974250760773741" P_Z="0.017622731153642754" Q="0.15116458429739316" RANDOM="YES" SCALE="6.8436985965185215" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="2.3734509997679374">
<NAME>Adverse effects: 1a. Extrapyramidal effects - average end point EPS score (high=poor)</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.182944259284263E-32" CI_END="4.239348214842481" CI_START="-0.6393482148424812" DF="0" EFFECT_SIZE="1.8000000000000003" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-002.02.01" MODIFIED="2010-08-03 15:17:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.14810389703512694" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.4462614032330399">
<NAME>vs 4 mg risperidone</NAME>
<CONT_DATA CI_END="4.239348214842481" CI_START="-0.6393482148424814" EFFECT_SIZE="1.8" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="0.8" MODIFIED="2010-04-26 17:57:53 +0100" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="5.3" SD_2="1.7" SE="1.2445882853377659" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.049837064211125" CI_START="-0.04983706421112499" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" MODIFIED="2010-08-03 15:17:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.05464904393039539" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.9216561050602197">
<NAME>vs 8 mg risperidone</NAME>
<CONT_DATA CI_END="5.049837064211125" CI_START="-0.04983706421112499" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="0.1" MODIFIED="2010-04-26 17:57:51 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="5.3" SD_2="2.4" SE="1.3009611831257688" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.30017561085158107" CI_END="12.57110672410101" CI_START="1.1581023748815737" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.8155770929272412" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.0993735134068943" LOG_CI_START="0.06374695220743806" LOG_EFFECT_SIZE="0.5815602328071661" METHOD="MH" MODIFIED="2010-08-03 15:17:56 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5837724397768536" P_Q="0.0" P_Z="0.027718244696403736" Q="0.0" RANDOM="YES" SCALE="29.218667281692987" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="200.0" Z="2.20125121129111">
<NAME>Adverse effects: 1b. Extrapyramidal effects - use of antiparkinson medication</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="45.42222706811206" CI_START="0.7925635162277901" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="1.6572684240202276" LOG_CI_START="-0.10096592325294032" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2010-08-03 15:17:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.08276495963375798" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.7348636461824245">
<NAME>vs 4 mg risperidone</NAME>
<DICH_DATA CI_END="45.42222706811206" CI_START="0.7925635162277901" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6572684240202276" LOG_CI_START="-0.10096592325294032" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2010-04-26 12:44:56 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.118449215931964" CI_START="0.6860567016617916" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="1.1178824983955729" LOG_CI_START="-0.163639988956248" LOG_EFFECT_SIZE="0.4771212547196624" MODIFIED="2010-08-03 15:17:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.14444924357919886" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.4594210944226251">
<NAME>vs 8 mg risperidone</NAME>
<DICH_DATA CI_END="13.118449215931964" CI_START="0.6860567016617916" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1178824983955729" LOG_CI_START="-0.163639988956248" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-04-26 12:44:54 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.7527726527090809" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.5666666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06639878946303382" CI_END="2.0705024972255397" CI_START="0.3806743026368802" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8877990168046207" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.31607575863970955" LOG_CI_START="-0.4194464391816363" LOG_EFFECT_SIZE="-0.05168534027096339" METHOD="MH" MODIFIED="2010-08-03 15:18:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7966541757348997" P_Q="0.0" P_Z="0.7829671704255552" Q="0.0" RANDOM="YES" SCALE="4.38" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="200.0" Z="0.2754543799217641">
<NAME>Cognitive functioning: Not improved (SKT)</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.550748330704528" CI_START="0.25090676030089926" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.40666761110760385" LOG_CI_START="-0.6004876371237167" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-08-03 15:18:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.706038770313687" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.37718144361687084">
<NAME>vs 4 mg risperidone</NAME>
<DICH_DATA CI_END="2.550748330704528" CI_START="0.25090676030089926" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.40666761110760385" LOG_CI_START="-0.6004876371237167" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-04-26 12:44:13 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.454197176819389" CI_START="0.2895028710899463" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.5383471248818377" LOG_CI_START="-0.5383471248818377" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-03 15:18:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>vs 8 mg risperidone</NAME>
<DICH_DATA CI_END="3.454197176819389" CI_START="0.2895028710899463" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5383471248818377" LOG_CI_START="-0.5383471248818377" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-26 12:44:11 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-05-11 16:14:21 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>ZOTEPINE versus REMOXIPRIDE - all short term outcomes</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="15.533874441653056" CI_START="-4.133874441653051" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.700000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2010-05-11 16:13:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.25593473652509047" Q="0.0" RANDOM="YES" SCALE="216.25405599867733" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.1360522018217227">
<NAME>Mental state: Average endpoint score (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Remoxipride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.533874441653056" CI_START="-4.133874441653051" EFFECT_SIZE="5.700000000000003" ESTIMABLE="YES" MEAN_1="40.6" MEAN_2="34.9" MODIFIED="2010-03-27 17:12:49 +0000" MODIFIED_BY="[Empty name]" ORDER="42" SD_1="18.6" SD_2="17.3" SE="5.017375073838805" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.6182213935281844" CI_START="-2.6182213935281844" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2010-05-11 16:14:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Adverse effects: 1a. Extrapyramidal effects - average end point EPS score (high=poor)</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Remoxipride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.6182213935281844" CI_START="-2.6182213935281844" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="2.6" MODIFIED="2010-03-31 16:20:38 +0100" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="5.3" SD_2="3.8" SE="1.3358517881860996" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.288286011579243" CI_START="0.4083599863460883" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9666666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.35951030573620957" LOG_CI_START="-0.3889568193776222" LOG_EFFECT_SIZE="-0.014723256820706345" METHOD="MH" MODIFIED="2010-05-11 16:14:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.9385362438333804" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="29" WEIGHT="100.0" Z="0.07710974105730928">
<NAME>Adverse effects: 1b. Extrapyramidal effects - use of antiparkinson medication</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Remoxipride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.288286011579243" CI_START="0.4083599863460883" EFFECT_SIZE="0.9666666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.35951030573620957" LOG_CI_START="-0.3889568193776222" LOG_EFFECT_SIZE="-0.014723256820706345" MODIFIED="2010-03-27 17:14:50 +0000" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.43965329426388716" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="29" VAR="0.19329501915708813" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8935088928322958" CI_START="0.2521009400630815" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6909090909090909" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.2772673491182791" LOG_CI_START="-0.5984255348731466" LOG_EFFECT_SIZE="-0.1605790928774337" METHOD="MH" MODIFIED="2010-04-26 18:09:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.4722568216373405" Q="0.0" RANDOM="YES" SCALE="67.05768728969393" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="38" WEIGHT="100.0" Z="0.7188119133167788">
<NAME>Cognitive functioning: Not improved (SKT)</NAME>
<GROUP_LABEL_1>Zotepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Remoxipride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.893508892832296" CI_START="0.25210094006308154" EFFECT_SIZE="0.6909090909090909" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.27726734911827916" LOG_CI_START="-0.5984255348731464" LOG_EFFECT_SIZE="-0.1605790928774337" MODIFIED="2010-03-27 17:16:34 +0000" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.5143863348062492" STUDY_ID="STD-Klieser-1991" TOTAL_1="20" TOTAL_2="38" VAR="0.2645933014354067" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-08-03 15:29:27 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-08-03 15:29:27 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-08-03 15:29:27 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU8AAAFECAIAAAAoaCtmAAAOPUlEQVR42u3dvY4cRReA4ZFICDZw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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-08-03 11:48:46 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-08-03 11:48:46 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-05-11 16:35:24 +0100" MODIFIED_BY="[Empty name]">Search strategy for the version of 2007</TITLE>
<APPENDIX_BODY MODIFIED="2010-08-03 11:48:46 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group Trials Register (April 2007) using the phrase: </P>
<P>[((zotepin* AND(amisulprid* OR aripiprazol*OR clozapin* OR olanzapin* OR quetiapin* OR sertindol* OR risperidon* OR ziprasidon*)) in title, abstract or index terms of REFERENCE) or ((zotepin* AND (amisulprid* OR aripiprazol* OR clozapin* OR olanzapin* OR quetiapin* OR sertindol* OR risperidon * OR ziprasidon*)) in interventions of STUDY)]</P>
<P>The Cochrane Schizophrenia Group Trials Register is maintained on Meerkat 1.5.1. This version of Meerkat stores references as studies. When an individual reference is selected through a search, all references which have been identified as the same study are also selected. This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group Module).</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>